Copyright CNW Group 2015
Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases
View original source (CNW)Resverlogix Corp. on 6ix
Earlier from Resverlogix
- Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference
- Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor
- International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"
- Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital
- Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
Later from Resverlogix
- Resverlogix Provides Research and Development Update in New York City
- Resverlogix Announces Voting Results
- Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum
- Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
- Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference
Follow Resverlogix into a list and get an email when it puts out news.
Follow Resverlogix